


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples** (monthly to 25/03/2024) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of February, the sector traded on a forward EV / EBITDA multiple of 9.8x, compared to the ASX200 on 8.8x.



**Average Values and Trading Multiples** (values as at 25/03/2024) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2024	EV/EBIT FY2024	Price / Earnings FY2024
Aged Care	1,197	11.2x	26.7x	34.2x
Animal Health	164	N/A	N/A	N/A
Biotech	155,488	8.0x	9.9x	30.4x
Hospitals & Clinics	46,696	9.2x	20.8x	31.6x
Medical Devices	21,836	21.9x	26.4x	35.5x
<b>Healthcare</b>	<b>225,688</b>	<b>10.9x</b>	<b>19.7x</b>	<b>31.3x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2024. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months.

## MERGER & ACQUISITION NEWS...

---

### ParagonCare

Value: AUD201.5m



**Paragon Care Ltd**, the Australia based provider of medical equipment, devices and consumables for healthcare market is to acquire **Clifford Hallam Healthcare Pty Ltd**, the local pharmaceutical and medical healthcare service provider from Lacaze Family Trust and Collins Millar Family Trust.



Value: Not Disclosed

**Yorkway Private**, the Australia based investment manager of private assets that focuses investing capital into mid-market growth companies, and debt into real estate secured opportunities has acquired an undisclosed stake in **Prestige Inhome Care**, the local provider of in-home care services.

## UNDER THE MICROSCOPE...

---

- **Health Care**, an Australian hospital owner, is undertaking a review of its business in the face of rising industry costs. Health Care said that outcomes from the review remain unclear, but hospitals could require changes to their workforce structure, compensation, rosters, processes, and policy. The company was acquired by Pacific Equity Partners for around AUD 400m in 2021.
- **Mater Health**, an Australia-based non-profit hospitals group owning and operating 11 hospitals in QLD, has been working with **KordaMentha's** restructuring team. KordaMentha is advising Mater Health on general business performance and on the financial performance of the group's hospitals.
- **Pacific Smiles Group Ltd** has received a revised AUD 1.75 cash per-share non-binding acquisition proposal from **Genesis Capital**. Pacific Smiles board has agreed to grant Genesis Capital the opportunity to conduct further DD, on a nonexclusive basis, to enable it to put forward a binding proposal.
- **Healthscope's** lenders are set to hire an investment bank or restructuring adviser to help with talks over debt repayments. Healthscope is not believe to be close to defaulting on its loans, but the hospital owner is facing concerns that it will encounter liquidity issues this financial year.
- The **Bluecross** board has signed an agreement to transfer the ownership of its residential and home care services to **Opal HealthCare**, a provider of residential aged care services with 101 Care Communities across Australia.
- Investment banks are believed to be angling for the mandate to help **Ramsay Health Care**, an Australia-based health care business, enhance shareholder returns. The item noted that expectations are rising that Ramsay will sell its European operations **Ramsay Sante**.
- **Healius** has initiated a comprehensive strategic review of its structure and assets. The decision cam after reporting a loss of AUD 635.8m. In its half-year earnings statement, Healius states that a non-cash impairment charge of AUD 603.2m had been recorded for the goodwill in its Pathology division.
- **ParagonCare**, an Australian healthcare wholesaler, distributor, and manufacturer, is merging with **CH2**, an Australian-based distributor and wholesaler of pharmaceuticals, medical consumables, and complementary medicines.

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Email
Sharon Doyle	Executive Chair	sdoyle@interfinancial.com.au
Brad Shaw	CEO	bshaw@interfinancial.com.au
Mark Steinhardt	Executive Director – M&A	msteinhardt@interfinancial.com.au
David Hassum	Director	dhassum@interfinancial.com.au
Andrew Wheeler	Director	awheeler@interfinancial.com.au
Anuk Manchanda	Director	amanchanda@interfinancial.com.au
Shaun Conroy	Director - Growth Advisory	sconroy@interfinancial.com.au
Derek Thomson	Director - Clean Energy & ESG	dthomson@interfinancial.com.au
Ian Goodwin	Director	igoodwin@interfinancial.com.au
Cameron Hall	Director - Consulting & Advisory	chall@interfinancial.com.au
Michael Kakanis	Associate Director	mkakanis@interfinancial.com.au
Jenny Zeng	Associate Director	jzeng@interfinancial.com.au
Nimerta Kumari	Associate Director	nkumari@interfinancial.com.au
Maggie Liu	Senior Consultant	mliu@interfinancial.com.au
Lucy Clarke	Associate	lclarke@interfinancial.com.au
Tahlia Micallef	Associate	tmicallef@interfinancial.com.au
Nasia Christodoulou	Analyst	nchristodoulou@interfinancial.com.au
Avi Ganasan	Research Analyst	aganasan@interfinancial.com.au

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person’s financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

<p><b>InterFinancial</b> Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---